Gurugram, India (September 02, 2026): DelveInsight’s “Liver Cirrhosis Pipeline Insight 2026” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Liver Cirrhosis Pipeline landscape. It covers the Liver Cirrhosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Liver Cirrhosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore Liver Cirrhosis Emerging Therapies, key Companies, and future treatment landscapes @ https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight

Key Takeaways from the Liver Cirrhosis Pipeline Report

• In August 2026, Boehringer Ingelheim advanced survodutide research in cirrhosis: The LIVERAGE™ trial is evaluating survodutide in people with MASH-associated cirrhosis, with the study designed to assess whether the investigational therapy can improve outcomes in this advanced liver-disease population.
• In August 2026, Resmetirom continued to be evaluated in compensated cirrhosis: An ongoing clinical study is assessing resmetirom 80 mg in people with well-compensated MASH/NASH cirrhosis, measuring whether treatment can delay major clinical outcomes.
• In August 2026, Semaglutide Research highlighted potential benefits in early cirrhosis: Researchers at UC San Diego reported that semaglutide showed statistically significant improvement in liver scarring among patients with advanced MASH, including individuals with compensated cirrhosis.
• DelveInsight’s Liver Cirrhosis pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Liver Cirrhosis treatment.
• The leading Liver Cirrhosis Companies such as Versantis AG, Mirum Pharmaceuticals, Sagimet Biosciences, TenNor Therapeutics, Prism Pharma, Vedanta Biosciences, Lipocine, Gwo Xi Stem Cell Applied Technology, Galectin Therapeutics, Resolution Therapeutics, Ipsen, and AstraZeneca and others.
• Promising Liver Cirrhosis Therapies such as IDN-6556, AZD2389, Resmetirom, GI262570 0.5 mg, Rifaximin SSD 40 mg IR tablet, NRL972, BMS-986263 and others.

Access DelveInsight’s in-depth Liver Cirrhosis Pipeline Analysis for a closer look at promising breakthroughs @ Liver Cirrhosis Clinical Trials and Studies

Liver Cirrhosis Overview

Liver cirrhosis is a condition in which the liver is scarred and permanently damaged, and scar tissue replaces healthy liver tissue, preventing the liver from working normally. Cirrhosis is usually caused by long-term liver damage from conditions such as alcohol-associated liver disease, nonalcoholic fatty liver disease, chronic hepatitis C, and chronic hepatitis B. Symptoms of cirrhosis may not appear until the liver is badly damaged and can include fatigue, severe itchy skin, and swelling in the legs and abdomen. Doctors diagnose cirrhosis based on medical history, a physical exam, and the results of tests such as blood tests, imaging tests, and liver biopsy. There is no specific cure for cirrhosis, but treating the underlying causes of cirrhosis may keep it from getting worse and may help prevent liver failure. Complications of cirrhosis can include portal hypertension, infections, and liver cancer. Eating a healthy diet and avoiding foods and drinks that can damage the liver, such as raw shellfish and alcohol, can help manage cirrhosis. In some cases, liver transplant may be an option.

Liver Cirrhosis Emerging Drugs Profile

• Elafibranor: Ipsen

Elafibranor (GFT-505) is under development for the treatment of colitis, non-alcoholic fatty liver disease, primary biliary cholangitis (PBC), and primary sclerosing cholangitis. The drug candidate is administered orally as a coated tablet. It acts by targeting peroxisome proliferator-activated receptor (PPAR) alpha and PPAR-beta / PPAR- delta. The drug candidate was under development for dyslipidemia, abdominal obesity, type 2 diabetes, Crohn’s disease, insulin resistance and glucose intolerance, colitis and NAFLD/NASH-induced hepatocellular carcinoma (HCC). Currently, the drug is in phase III stage of its clinical trial.

• AZD2389: AstraZeneca

AZD2389 is a hepatoprotectant small molecule developed by AstraZeneca. It is designed to provide protection to the liver. The drug is part of a class aimed at treating liver-related diseases or conditions. Currently, the drug is in Phase II stage of its clinical trial for the treatment of liver Cirrhosis.

• PHIN-214: PharmaIN

PHIN-214 is an investigational drug currently undergoing Phase Ib safety trials by harmaIN, aimed at treating refractory ascites, a condition for which no FDA-approved pharmacological therapy currently exists. Its mechanism of action (MOA) involves targeting and shutting down the Renin-Angiotensin-Aldosterone System (RAAS) signaling pathway, which plays a key role in the retention of excess salt and water by the kidneys. By inhibiting this pathway, PHIN-214 seeks to prevent the accumulation of ascitic fluid, offering potential therapeutic benefits for patients with liver disease who no longer respond to diuretic treatments.

The Liver Cirrhosis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Liver Cirrhosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liver Cirrhosis Treatment.
• Liver Cirrhosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Liver Cirrhosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liver Cirrhosis market.

Explore DelveInsight’s expert-driven Liver Cirrhosis Pipeline Report today! @ Liver Cirrhosis Unmet Needs

Liver Cirrhosis Companies

Versantis AG, Mirum Pharmaceuticals, Sagimet Biosciences, TenNor Therapeutics, Prism Pharma, Vedanta Biosciences, Lipocine, Gwo Xi Stem Cell Applied Technology, Galectin Therapeutics, Resolution Therapeutics, Ipsen, and AstraZeneca and others.

Liver Cirrhosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Liver Cirrhosis Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Download DelveInsight’s latest report to gain strategic insights into upcoming Therapies @ Liver Cirrhosis Market Drivers and Barriers, and Future Perspectives

Scope of the Liver Cirrhosis Pipeline Report

• Coverage- Global
• Liver Cirrhosis Companies- Versantis AG, Mirum Pharmaceuticals, Sagimet Biosciences, TenNor Therapeutics, Prism Pharma, Vedanta Biosciences, Lipocine, Gwo Xi Stem Cell Applied Technology, Galectin Therapeutics, Resolution Therapeutics, Ipsen, and AstraZeneca and others.
• Liver Cirrhosis Therapies- IDN-6556, AZD2389, Resmetirom, GI262570 0.5 mg, Rifaximin SSD 40 mg IR tablet, NRL972, BMS-986263 and others.
• Liver Cirrhosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Liver Cirrhosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive Liver Cirrhosis Pipeline Report @ Liver Cirrhosis Emerging Drugs and Major Companies

Table of Content

1. Introduction
2. Executive Summary
3. Liver Cirrhosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Liver Cirrhosis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Elafibranor: Ipsen
9. Mid Stage Products (Phase II)
10. Volixibat: Mirum Pharmaceuticals
11. Early Stage Products (Phase I)
12. Mid Stage Products (Phase II)
13. Preclinical Stage Products
14. PVT201: Parvus Therapeutics
15. Inactive Products
16. Liver Cirrhosis Collaborations Assessment- Licensing / Partnering / Funding
17. Liver Cirrhosis Unmet Needs
18. Liver Cirrhosis Market Drivers and Barriers
19. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/liver-cirrhosis-pipeline-insight